Savara Inc. (SVRA)
After hours:
- Business Wire
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
LANGHORNE, Pa., May 09, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and provided a business update.
- Business Wire
Savara to Present at the Citizens JMP Life Sciences Conference
LANGHORNE, Pa., May 07, 2024--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am PT/9:00am ET. A live webcast of the fireside chat will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.
- Business Wire
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
LANGHORNE, Pa., April 08, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, CA.
